Lesson
Build the Immune Enteropathy
Celiac disease is a permanent immune-mediated response to dietary gluten in a genetically susceptible person. The small intestine is the principal injury site, but the clinical consequences extend throughout the body.
- Gluten peptides
- HLA-DQ2 and HLA-DQ8
- Tissue transglutaminase
- Villous atrophy
- Malabsorption
Wheat, barley, and rye supply the trigger while the patient is consuming gluten.
Tissue transglutaminase modification and antigen presentation support an adaptive immune response.
Inflammation, crypt hyperplasia, and villous atrophy reduce absorption and create systemic consequences.
Begin with susceptibility and exposure
Gluten proteins from wheat, barley, and rye supply immunogenic peptides. Most affected patients carry HLA-DQ2 or HLA-DQ8, but these haplotypes are common and do not establish the diagnosis by themselves.
Connect transglutaminase to adaptive immunity
Tissue transglutaminase modifies gluten peptides, which can be presented to T cells in a compatible HLA context. The resulting immune response drives intestinal inflammation and supports production of disease-associated antibodies.
Read the mucosal injury
Increased intraepithelial lymphocytes, crypt hyperplasia, and villous atrophy reduce absorptive surface. Histology must be interpreted with serology, diet status, and competing causes because villous injury is not unique to celiac disease.
Translate injury into physiology
Iron, folate, calcium, vitamin D, and other nutrients may be affected. Diarrhea, weight loss, anemia, low bone density, growth failure, and extraintestinal symptoms can follow even when abdominal symptoms are mild.
Quick check
Lesson
Recognize the Full Clinical Spectrum
Celiac disease may present through the gut, skin, blood, bone, liver, nervous system, fertility, or growth. Case finding depends on recognizing patterns rather than waiting for a single classic phenotype.
- Diarrhea and bloating
- Iron deficiency
- Bone disease
- Dermatitis herpetiformis
- Growth and reproduction
Diarrhea, pain, bloating, weight loss, nausea, or constipation can appear across ages.
Iron deficiency, low bone density, elevated liver tests, neuropathic symptoms, and fatigue can dominate.
Family history, type 1 diabetes, thyroid disease, IgA deficiency, and growth concerns support case finding.
Recognize gastrointestinal presentations
Chronic diarrhea, steatorrhea, abdominal pain, bloating, weight loss, nausea, and constipation can occur. Children may present with constipation, poor growth, delayed puberty, irritability, or abdominal distention.
Find extraintestinal disease
Iron-deficiency anemia, folate deficiency, low bone density, fractures, elevated aminotransferases, neuropathic symptoms, dental enamel changes, aphthous ulcers, headache, and fatigue can bring the patient to care.
Use risk context
A first-degree relative with confirmed celiac disease, type 1 diabetes, autoimmune thyroid disease, selective IgA deficiency, and selected genetic syndromes can increase pretest probability. Testing remains guided by the clinical context.
Do not collapse the differential
Irritable bowel syndrome, inflammatory bowel disease, infection, pancreatic insufficiency, food intolerance, medication injury, and other enteropathies can overlap. A gluten-free response alone does not prove celiac disease.
Quick check
Lesson
Preserve Accuracy Before Changing the Diet
Serology is most informative while the patient is eating gluten. Starting a gluten-free diet before testing can lower antibody concentrations and complicate confirmation.
- tTG-IgA
- Total IgA
- IgA deficiency
- Gluten-containing diet
- Pretest probability
Testing after gluten withdrawal can reduce antibody concentrations and diagnostic sensitivity.
The total IgA result determines whether an IgA-based negative screen can be trusted.
High-probability disease can require biopsy even when screening serology is negative.
Test during gluten exposure
Measure tissue transglutaminase IgA while the patient is on a regular gluten-containing diet. Do not ask a patient to begin a gluten-free diet before the diagnostic plan is established.
Measure total IgA
Concurrent total IgA identifies patients in whom an IgA-based assay may be falsely reassuring. In IgA deficiency, use an IgG-based strategy such as tTG-IgG or deamidated gliadin peptide IgG according to the diagnostic pathway.
Interpret probability, not a number alone
A negative tTG-IgA with normal total IgA has strong rule-out value when pretest probability is low or moderate. High clinical suspicion can still justify endoscopy with duodenal biopsy.
Avoid obsolete shortcuts
Native antigliadin antibody testing is not the preferred modern screening strategy. A positive result requires confirmation in the correct clinical and histologic context rather than immediate lifelong dietary treatment.
Quick check
Lesson
Confirm the Diagnosis in the Right Context
For most patients, diagnosis integrates serology with upper endoscopy and multiple duodenal biopsies. Genetics and nonbiopsy pathways answer narrower questions.
- EGD
- Duodenal bulb
- Distal duodenum
- HLA exclusion
- Selected nonbiopsy criteria
Multiple specimens reduce the chance that patchy injury is missed.
Villous injury is interpreted with serology, gluten exposure, medicines, and competing enteropathies.
Absence of compatible HLA can rule out disease; presence does not prove it.
Sample the duodenum adequately
Upper endoscopy should obtain multiple specimens because injury can be patchy. Current ACG guidance describes one or two biopsies from the bulb and four from the distal duodenum.
Use histology with context
Villous atrophy and intraepithelial lymphocytosis support celiac disease when the patient is exposed to gluten and serology fits. Infection, immune deficiency, medication injury, and other enteropathies remain in the differential.
Use HLA testing mainly to exclude
Absence of a celiac-compatible HLA haplotype makes celiac disease very unlikely and can clarify discrepant or already gluten-free cases. Presence is common and does not confirm disease.
Respect the limits of nonbiopsy diagnosis
Selected children may use a high tTG-IgA threshold with confirmatory endomysial antibody in a second sample when the family accepts the strategy. Adults generally require biopsy; in selected symptomatic adults unable or unwilling to undergo endoscopy, similar serology can support a likely diagnosis rather than full histologic confirmation.
Quick check
Lesson
Build a Sustainable Gluten-Free Diet
A strict lifelong gluten-free diet is the disease-modifying treatment. Success requires more than a prohibited-food list because nutrition, cost, cross-contact, culture, and daily routines determine whether the plan is livable.
- Wheat, barley, and rye
- Less than 20 ppm
- Cross-contact
- Gluten-free oats
- Expert dietitian
FDA-regulated gluten-free claims use a less-than-20-ppm threshold and ingredient rules.
Shared fryers, toasters, surfaces, flour dust, and preparation systems can transfer gluten.
Nutrition, culture, cost, food access, oats, and unnecessary restriction require individual planning.
Remove the disease trigger
Avoid wheat, barley, rye, and ingredients derived from them unless processed and labeled in a manner that meets gluten-free requirements. Malt commonly derives from barley and requires careful label review.
Understand the US food claim
FDA-regulated food labeled gluten-free must contain less than 20 parts per million of gluten and meet ingredient restrictions. A voluntary claim does not eliminate the need to assess the product and the patient's context.
Prevent cross-contact
Shared fryers, toasters, cutting surfaces, bulk bins, flour dust, condiments, preparation tools, and restaurant workflows can introduce gluten. The response should be practical risk reduction, not indiscriminate food avoidance.
Use oats deliberately
Gluten-free oats are appropriate for most patients, but contamination and a small risk of avenin sensitivity require monitoring for symptoms and serologic relapse when introduced.
Partner with an expert dietitian
A dietitian experienced in celiac disease should assess adherence, nutritional adequacy, food access, culture, eating patterns, and avoidable restriction. Dietitian interview remains the standard adherence assessment.
Quick check
Lesson
Repair Deficits and Protect Long-Term Health
Removing gluten stops the trigger, but established deficiencies and preventive-care gaps still require direct assessment and treatment.
- Iron and folate
- Vitamin D and calcium
- Bone density
- Growth
- Pneumococcal vaccination
Blood counts, iron, folate, B12, vitamin D, calcium, and other tests follow the phenotype.
Replace documented deficits and track skeletal risk, weight, growth, and pubertal development.
Pneumococcal prevention follows current age, risk, prior-dose, and asplenia guidance.
Assess likely deficiencies
Use history, examination, blood counts, iron studies, folate, vitamin B12, vitamin D, calcium, liver tests, and other studies in proportion to the presentation. Replace documented deficits while the intestine heals.
Protect the skeleton
Evaluate calcium and vitamin D intake, fracture history, menopausal status, glucocorticoid exposure, and other bone risks. Bone-density testing is individualized rather than automatically identical for every patient.
Follow children as children
Track height, weight, growth velocity, pubertal development, symptoms, serology, and nutrition. Catch-up growth is an outcome, not a reason to stop follow-up.
Review immunization
ACG suggests pneumococcal vaccination for patients with celiac disease. The specific regimen should follow current age, risk, prior-vaccine, and functional-asplenia guidance rather than an outdated fixed schedule.
Avoid untargeted replacement
A gluten-free label does not make a supplement necessary or safe. Choose replacement from a documented need, product quality, interactions, and a monitoring endpoint.
Quick check
Lesson
Treat Dermatitis Herpetiformis Without Missing Systemic Risk
Dermatitis herpetiformis is an intensely pruritic celiac-associated blistering eruption. A gluten-free diet treats the underlying disease; dapsone can control skin symptoms quickly but does not heal the gastrointestinal component.
- Pruritic grouped lesions
- Gluten-free diet
- Dapsone
- Hemolysis
- Blood and liver monitoring
A strict gluten-free diet addresses both intestinal and skin disease over time.
Dapsone can rapidly reduce pruritus and lesions but does not heal intestinal disease.
CBC, hemoglobin, liver tests, G6PD context, cyanosis, rash, fever, and weakness belong in the safety plan.
Recognize the phenotype
Dermatitis herpetiformis commonly produces intensely pruritic grouped papules or vesicles on extensor surfaces. Scratching can obscure intact blisters. Dermatology evaluation and appropriate biopsy support diagnosis.
Keep the diet foundational
A strict gluten-free diet addresses the intestinal and skin disease but skin improvement can be slow. Dapsone may provide rapid symptom control while dietary treatment takes effect.
Use the label deliberately
The current US label starts adults at 50 mg daily and titrates individually, usually within 50 to 300 mg daily, then reduces to the minimum maintenance exposure. Dosing and duration require clinician supervision.
Anticipate hematologic toxicity
Dose-related hemolysis and methemoglobin formation can occur with or without G6PD deficiency and may be worse with G6PD deficiency. Severe anemia should be corrected, hemoglobin monitored, and cardiopulmonary disease considered.
Monitor beyond hemoglobin
The label calls for frequent complete blood counts, baseline and subsequent liver-function monitoring when feasible, and urgent response to fever, sore throat, pallor, purpura, jaundice, new rash, cyanosis, dyspnea, or muscle weakness. Dapsone can also falsely lower HbA1c.
Quick check
Lesson
Resolve Medication Gluten Questions by Exact Product
Medication excipient concerns should be handled precisely. Broad warnings that every tablet may contain harmful gluten can produce unnecessary fear, nonadherence, and delayed treatment.
- Exact NDC or product
- Inactive ingredients
- Wheat starch
- DailyMed
- Manufacturer confirmation
Manufacturer, strength, dosage form, imprint, and NDC distinguish products with different excipients.
Review DailyMed, OTC inactive ingredients, and manufacturer information when needed.
Most US oral medicines contain no or virtually no gluten, so unverified fear should not stop needed care.
Begin with the current FDA position
FDA reports that most oral drug products contain no or virtually no gluten and knows of no currently marketed US oral drug products with wheat gluten or wheat flour intentionally added. A small number may use wheat starch.
Match the exact product
Generic names do not identify excipients. Verify manufacturer, strength, dosage form, imprint, NDC when available, and the actual dispensed product before reviewing inactive ingredients.
Use current product information
DailyMed labeling and the OTC Drug Facts inactive-ingredient section can support review. If the source, manufacturing process, or product identity remains uncertain, contact the manufacturer or pharmacy supply chain.
Calibrate the risk message
FDA estimates that even rare wheat-derived ingredient use would contribute very little gluten per oral dose. Patients with unusual sensitivity, refractory disease, or unresolved product information need individualized review, not automatic discontinuation of clinically necessary medicine.
Document the resolution
Record the exact product, source checked, conclusion, date, and contingency if the manufacturer changes. Recheck after a product switch because inactive ingredients can differ.
Quick check
Lesson
Measure Recovery Beyond Symptom Relief
Symptoms can improve before serology or mucosa, and serology does not perfectly predict healing. Follow-up should measure the domains that matter rather than treating one normal result as completion.
- Dietitian review
- tTG trend
- Nutrient recovery
- Growth
- Mucosal healing
Dietitian interview remains the standard adherence assessment and can find both exposure and overrestriction.
Falling tTG supports response but does not independently prove mucosal healing.
Persistent disease and selected adult follow-up can justify repeat duodenal assessment.
Establish a baseline
Record symptoms, weight, growth in children, diet, key deficiencies, serology, bone risk, vaccination status, and comorbid autoimmune disease. A baseline makes later improvement interpretable.
Use expert dietary assessment
Dietitian interview remains the standard method for assessing adherence. Commercial gluten-detection tools are not routinely recommended because they may not distinguish clinically important from trivial exposure.
Trend serology thoughtfully
Falling tTG supports reduced immune activity and adherence, but symptoms and serology correlate imperfectly with mucosal healing. A normalized antibody result does not prove healed intestine.
Consider mucosal reassessment
Endoscopy with biopsy is useful when symptoms persist or recur despite a gluten-free diet. In asymptomatic adults, follow-up biopsy after about two years can be considered through shared decision-making; routine follow-up biopsy is not recommended for asymptomatic children.
Define success broadly
Meaningful recovery can include symptom control, corrected anemia, nutrient repletion, weight or growth recovery, improved bone health, normalized liver tests, and sustained function without excessive dietary restriction.
Quick check
Lesson
Investigate Persistent Disease Systematically
Persistent or recurrent symptoms after treatment are common enough to require a process. Refractory celiac disease is rare and should not be diagnosed before the original diagnosis, diet, and competing conditions are reassessed.
- Inadvertent gluten
- Diagnostic review
- Competing disorders
- Repeat biopsy
- Refractory celiac disease
Review original gluten exposure, serology, biopsy quality, HLA context, and alternative enteropathies.
Dietary review and phenotype-directed testing address contamination, intolerance, IBS, SIBO, pancreatic disease, and colitis.
Villous atrophy despite verified long-term treatment requires specialist classification and complication assessment.
Reconfirm the diagnosis
Review original serology, gluten exposure at testing, endoscopy, biopsy location and interpretation, HLA context when relevant, and alternative causes of villous atrophy.
Assess dietary exposure without blame
Inadvertent gluten is a common explanation. An expert dietitian should review foods, supplements, restaurants, shared preparation, medicines, and overly restrictive compensatory behaviors.
Test competing explanations selectively
Lactose or fructose intolerance, irritable bowel syndrome, microscopic colitis, pancreatic insufficiency, small-intestinal bacterial overgrowth, inflammatory bowel disease, infection, and medication effects can produce persistent symptoms.
Use repeat endoscopy when needed
Ongoing symptoms, malabsorption, weight loss, anemia, or concerning laboratory change can require repeat EGD with biopsies to assess healing and identify persistent enteropathy or another disorder.
Refer suspected refractory disease
Refractory celiac disease means persistent symptoms or malabsorption with villous atrophy despite strict gluten-free treatment for at least 12 months after other causes are excluded. It is rare, has serious complications, and requires expert multidisciplinary care.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 104 question bank.
Each attempt draws a fresh set and rearranges the answer choices.